COMMUNIQUÉ DE PRESSE

par SynBiotic SE (isin : DE000A3E5A59)

SYNBIOTIC acquires Ilesol: Enormous competitive advantages through cannabinoid extracts and isolates from own production

EQS-News: SynBiotic SE / Key word(s): Takeover
SYNBIOTIC acquires Ilesol: Enormous competitive advantages through cannabinoid extracts and isolates from own production

23.04.2024 / 10:33 CET/CEST
The issuer is solely responsible for the content of this announcement.


The German industrial hemp and cannabis group SYNBIOTIC SE acquires Ilesol Pharmaceuticals from Varaždin/Croatia. Ilesol has a 3,400 m2 production facility for the manufacture of cannabinoid extracts and isolates. The company also produces and distributes its own CBD natural cosmetics range. With the acquisition of Ilesol, SYNBIOTIC will be able to produce CBD isolates with the "Made in EU" label and distribute them through the companies of the SYNBIOTIC Group.

"We are thus integrating another crucial process step into our supply chain," says Daniel Kruse, Managing Director of SYNBIOTIC. "The in-house production and refinement of hemp and cannabis extracts and corresponding isolates is an enormous competitive advantage. The market for hemp extracts and CBD isolates alone is a growth market worth billions. The cosmetics industry has long since discovered hemp and CBD for itself and demand is increasing significantly. And if the EU Commission decides in favour of the numerous novel food applications next year, the demand for hemp extracts and CBD isolates in the food supplement sector will increase many times over."

"The acquisition of Ilesol is therefore strategically significant news for our group of companies and investments. And for our investors and shareholders, it is the second successful takeover in four months after Bushdoctor," adds Kruse.

SYNBIOTIC is ideally positioned in the CBD product segment with leading brands and, in future, Ilesol. What was missing until now was an independent production facility for refining the extracts and manufacturing isolates that was not dependent on external factors. Ilesol closes precisely this gap in the supply chain. Moreover, the additional cosmetics range from Ilesol fits perfectly into the distribution programme of SYNBIOTIC's subsidiaries Solidmind and Hempro International.

"As part of the SYNBIOTIC group of companies, we can take the next steps together on a European level. As an experienced manufacturer with independent, technologically mature production processes, we will be an absolute asset to everyone involved in SYNBIOTIC in every respect," explains Sasha Bajilo, CEO and Co-Founder, Ilesol Pharmaceuticals.

The declared aim of CEO Daniel Kruse is to establish SYNBIOTIC as the leading group of companies for industrial hemp and cannabis not only on the German market, but also on the European market. With the acquisitions of Bushdoctor and Ilesol, SYNBIOTIC is now also active in Austria and Croatia.

"The Group's pan-European orientation is the logical step towards a strong market position throughout Europe. This not only completes our supply chain and increases our sales potential, but also increases SYNBIOTIC's importance for large, strategic investors from outside Europe," says Kruse.

About Ilesol Pharmaceuticals
Ilesol Pharmaceuticals is an industrial manufacturer of cannabinoid extracts and CBD isolates specialising in cosmetic ingredients, cosmetic products and dietary supplements. The company, based in Varaždin /Croatia, has its own production facility with an area of 3,400 metres2 and covers the entire production process.

Publisher
SYNBIOTIC SE
Daniel Kruse
Managing Director
Münsterstrasse 336
40470 Düsseldorf
Germany

Media contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 171 3677028
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the hemp and cannabis sector and pursues a buy and build investment strategy focussed on the EU. The group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The core businesses of the vertically integrated company are research and development, production and commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC has a clear strategy to further expand along the value chains of its business areas - hemp and CBD, medical cannabis and consumer cannabis.


23.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language:English
Company:SynBiotic SE
Münsterstr. 336
40470 Dusseldorf
Germany
E-mail:office@synbiotic.com
Internet:https://www.synbiotic.com/
ISIN:DE000A3E5A59
WKN:A3E5A5
Listed:Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange
EQS News ID:1887037

 
End of NewsEQS News Service

1887037  23.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1887037&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6
Voir toutes les actualités de SynBiotic SE